<DOC>
	<DOC>NCT00141921</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe psoriasis.</brief_summary>
	<brief_title>Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis</brief_title>
	<detailed_description>This study was a multicenter, open-label extension study for pediatric patients who participated in Study 20030211 (NCT00078819).</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Enrollment on previous Amgen study 20030211 (NCT00078819) Serious or clinically significant adverse event on Amgen study 20030211 related to etanercept</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Immunex</keyword>
	<keyword>Amgen</keyword>
	<keyword>Pediatric,</keyword>
	<keyword>plaque psoriasis</keyword>
	<keyword>clinical trial</keyword>
</DOC>